Skip to main content
Log in

Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

A series of continuous human tumour cell lines, derived from various tumour types, were used to establish whether the combination of spirogermanium (SP) with other ‘standard’ antitumour drugs proved superior to these as single agents in reducing cell survival in vitro. A non-cytotoxic concentration of SP was selected and when combined with a range of concentrations of cisplatin or 5-fluorouracil (5-FU), definite synergistic cell kill was noted in all lines tested. In contrast, the combination of SP with various other antitumor drugs, including adriamycin, methotrexate and the vinca alkaloids and with X-irradiation did not enhance cytotoxicity.

These pre-clinical in vitro studies suggest that benefit may accrue from combining SP with either 5-FU or cisplatin and provide a basis for their clinical evaluation in colo-rectal tumours or transitional cell cancer of the bladder, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rice LM, Wheeler JW, Geschickter CF: Spirans XXII. Synthesis of 4,4-dialkyl-4-germacyclohexanone and 8,8-dialkyl-8-germaazaspiro (4,5) decanes. J Heterocycl Chem 11:1041–1946, 1974

    Google Scholar 

  2. Schein PS, Slavik M, Smyth T, Hoth D, Smith F, MacDonald JS, Wooley PV: Phase I clinical trial of spirogermanium. Cancer Treat Rep 64:1051–1056, 1980

    Google Scholar 

  3. Mattsson W: A phase I study of spirogermanium. (Abstract) Proc Am Assoc Cancer Res 21:194, 1980

    Google Scholar 

  4. Budman DR, Schulman P, Vinciguerra V, Degman T: A phase I trial of spirogermanium given by infusion in a multiple-dose schedule. Cancer Treat Rep 66:173–175, 1982

    Google Scholar 

  5. Weiselberg L, Budman DR, Schulman P, Vinciguerra W, Degman TJ, Pasmantier M: Phase II trial of spirogermanium in advanced epithelial carcinoma of the ovary. Cancer Treat Rep 66:1675–1676, 1982

    Google Scholar 

  6. Budman DR, Ginsberg S, Perry M, Weinberg V, Schein P, Hanson J, Coleman M, Wood W: Phase II trial of spirogermanium in breast adenocarcinoma: a cancer and leukemia group B study. Cancer Treat Rep 66:1667–1668, 1982

    Google Scholar 

  7. Falkson G, Falkson HC: Phase II trial of spirogermanium for advanced breast cancer. Cancer Treat Rep 67:189–190, 1983

    Google Scholar 

  8. Legha SS, Ajani JA, Bodey GP: Phase I study of spirogermanium given daily. J Clin Oncol 1:331–336, 1983

    Google Scholar 

  9. Mulinos MG, Amin P: Toxicology and phase I study of a new anticancer agent, spirogermanium HCl. Fed Proc 39:747, 1980

    Google Scholar 

  10. Yang S-J, Rafla S: Effect of spirogermanium on V79 Chinese hamster cells. Am J Clin Oncol 5:331–337, 1983

    Google Scholar 

  11. Hill BT, Whatley SA, Bellamy AS, Jenkins LY, Whelan RDH: Cytotoxic effects and biological activity of 2-aza-8-germanspiro-[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro. Cancer Res 42:2852–2856, 1982

    Google Scholar 

  12. Hill BT, Metcalfe SA, Hepburn PJ, Masters JRW, Whelan RDH: Evaluation of spirogermanium in murine and human tumour lines in vitro and demonstration of synergy with cisplatin or 5-fluorouracil. Proceedings of 13th International Congress of Chemotherapy, Vienna. Part 257, 30–33, 1983

    Google Scholar 

  13. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterisation of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16–23, 1979

    CAS  PubMed  Google Scholar 

  14. Hill BT, Whelan RDH: Attempts to optimise colony-forming efficiencies using three different survival assays and a range of human tumour continuous cell lines. Cell Biol Int Rep 7:617–624, 1983

    Google Scholar 

  15. Hastings RJ, Franks LM: Chromosome pattern, growth in agar and tumorigenicity in nude mice of four human bladder carcinoma cell lines. Int J Cancer 27:15–21, 1983

    Google Scholar 

  16. Horwitz KB, Costlow ME, McGuire WL: A human breast cancer cell line with estrogen, androgen, progesterone and glucocorticoid receptors. Steroids 26:785–795, 1975

    Google Scholar 

  17. Alberts DS, Chen H-SG: Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: SE Salmon (ed): Cloning of Human Tumor Stem Cells. Alan R Liss Inc, New York, 1980, pp 351–359

    Google Scholar 

  18. Hill BT, Whelan RDH, Rupniak HT, Dennis LY, Rosholt MA: A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry. Cancer Chemother Rep 7:21–26, 1981

    Google Scholar 

  19. Rupniak HT, Whelan RDH, Hill BT: Concentration and time-dependent inter-relationships for antitumors drug cytotoxicities against tumour cells in vitro. Int J Cancer 32:7–12, 1983

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hill, B.T., Bellamy, A.S., Metcalfe, S. et al. Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro . Invest New Drugs 2, 29–33 (1984). https://doi.org/10.1007/BF00173784

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173784

Key words

Navigation